Finally, we found afatinib and neratinib to be highly active against human HER2 mutant cervical cancer xenografts. Indeed, as shown in Fig. 3C, daily oral administration of afatinib at 25 mg/kg or neratinib at 40 mg/kg showed a significant tumor growth inhibition in the treated group after 30 d of treatment (P = 0.001 and P = 0.0002, respectively) and significantly improved the overall survival when compared to the control group (P = 0.0001 and P = 0.0001, respectively) (Fig. 3D).